Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage, and intracystic recombinant interleukin-2

Irene Velasco, Adolfo Campos, Campos A, Acién P, Pedro Acién
Fertility and sterility · 2005 · vol. 83(4) , pp. 873–877 · doi:10.1016/j.fertnstert.2004.10.035 · PMID:15820793 · W2054289218
article OA: closed CC0 ⤵ 8 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study investigated cytokine level changes in ovarian endometriosis patients following treatment with GnRH analogue, ultrasound-guided drainage, and intracystic IL-2.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo determine the changes in cytokine levels from women with endometriomas who are treated with recombinant interleukin-2 after ultrasound-guided cyst aspiration, and to relate these changes to the clinical results observed in these patients.DesignA double-blind randomized controlled trial.SettingUniversity hospital.Patient(s)Twenty-four women with endometriosis-related symptoms and endometriomas.Intervention(s)Endometriomas in women receiving GnRH analogues and undergoing transvaginal ultrasound-guided cyst aspiration were injected with dextrose that did or did not contain recombinant interleukin-2 (IL-2). Serum samples were collected before and after treatment.Main outcome measure(s)Serum samples were analyzed by enzyme immunoassay to determine the levels of IL-1beta, IL-2, IL-6, IL-8, IL-10, IL-12, IL-13, and IL-17.Result(s)The cytokine levels after treatment with GnRH analogues and recombinant IL-2 were similar to the initial levels. The patients receiving GnRH analogues without IL-2 had higher IL-1, IL-2, IL-8, and IL-13 levels. Good clinical results were observed in 90% of the patients in the first group but in only 30% of the second one.Conclusion(s)Administration of recombinant IL-2 intracystically decreases cytokine production in women with endometriomas. These results have important implications for the design of future therapies based on immunomodulation, such as using higher or repeated doses of recombinant IL-2 in the cysts.

My notes (saved in your browser only)

Condition tags

mesh:D004716endometriosis

MeSH descriptors

Antineoplastic Agents Antineoplastic Agents, Hormonal Cytokines Endometritis Interleukin-2 Ovarian Diseases Triptorelin Pamoate Adult Antineoplastic Agents Antineoplastic Agents, Hormonal Cytokines Drainage Drug Therapy, Combination Endometritis Endometritis Endometritis Female Humans Immunologic Factors Immunologic Factors

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (34)

Cited by (8)

Source provenance

europepmc
last seen: 2026-07-26T06:08:39.051465+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:15:41.664291+00:00
unpaywall
last seen: 2026-06-13T06:42:57.164913+00:00
License: CC0 · commercial use OK